Don't Just Read the News, Understand It.

Browser Extension

Sunday, June 1, 2025

US Edition

Subscribe Login

Israel-Hamas Conflict

Champions League

Paris Saint-Germain

Artificial Intelligence

Natural Disasters

Pharmaceutical-technology.com image

News from Pharmaceutical-technology.com

Topics Most Covered by pharmaceutical-technology.com

Artificial Intelligence

Sources Covering Similar Topics

biopharmadive.com

Clinical Trials Arena

biopharmadive.com

Suggest a source

Looking for a source we don't already have? Suggest one here.

News Home Page Local News Blindspot Feed International Covid-19

International North America South America Europe Asia Australia Africa

Trending Internationally Champions League Paris Saint-Germain Motorsports Social Media NCAA

Trending in U.S.Israel-Hamas Conflict NCAA Baseball Donald Trump New York Knicks

Trending in U.K.Israel-Hamas Conflict Manchester United Premier League UK Economy Nigel Farage

Trending Topics

Champions League Paris Saint-Germain Motorsports Social Media Israel-Hamas Conflict

CompanyAbout History Mission Blog Testimonials Group Subscriptions Subscribe Gift Free Trial Careers Affiliates

HelpHelp Center FAQ Contact Us For Educators/Libraries Media Bias Ratings Ownership and Factuality Ratings Referral Code News Sources Topics

ToolsApp Browser Extension Daily Newsletter Blindspot Report Newsletter Burst Your Bubble Newsletter Timelines

Gift Privacy Policy Manage Cookies Terms and Conditions

© 2025 Snapwise Inc

Search Blindspot Local

News from Pharmaceutical-technology.com

See all of Pharmaceutical-technology.com’s headline news. Compare how the top news stories are covered by left-wing and right-wing news sources.

In total, 367 have been published by Pharmaceutical-technology.com which Ground News has aggregated in the past 3 months.

Ground News rates Pharmaceutical-technology.com’s media bias as unknown. . Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, All Sides, and Media Bias/Fact Check.

Pharmaceutical-technology.com’s factuality rating is Unknown. Ground News calculates this rating using a combination of the fact and reliability ratings from Ad Fontes Media and Media Bias/Fact Check.

See all of Pharmaceutical-technology.com’s headline news. Compare how the top news stories are covered by left-wing and right-wing news sources. In total, 367 have been published by Pharmaceutical-technology.com which Ground News has aggregated in the past 3 months.

Ground News rates Pharmaceutical-technology.com’s media bias as unknown. . Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, All Sides, and Media Bias/Fact Check. Pharmaceutical-technology.com’s factuality rating is Unknown. Ground News calculates this rating using a combination of the fact and reliability ratings from Ad Fontes Media and Media Bias/Fact Check.

Information about Pharmaceutical-technology.com

Where is Pharmaceutical-technology.com located?Pharmaceutical-technology.com's Website

Media Bias Ratings

Do you diasgree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top Pharmaceutical-technology.com News

Astellas Adds to Claudin Clout with $1.3bn+ Evopoint Deal

Cancer · Hong Kong

Astellas Adds to Claudin Clout with $1.3bn+ Evopoint Deal

59% Center coverage: 24 sources

Astellas was the first company to bring a drug against the claudin target CLDN18.2 to market, and has now added another to its cancer pipeline See the Story

Moderna pulls application for COVID-flu combination shot

Moderna · United States

Moderna pulls application for COVID-flu combination shot

47% Right coverage: 15 sources

Moderna said on Wednesday it has withdrawn an application seeking approval for its flu and COVID combination vaccine candidate to wait for efficacy data from a late-stage trial of its influenza shot, which is due later this year. See the Story

New three-drug combination could help women with aggressive breast cancer live longer, study suggests

NHS · United Kingdom

New three-drug combination could help women with aggressive breast cancer live longer, study suggests

66% Center coverage: 6 sources

Breaking News Topics Related to Pharmaceutical-technology.com

United Kingdom

Health

Pharma

United States

Medical

Similar News Topics

biopharmadive.com

Clinical Trials Arena

STAT

Pharmaphorum

Endpoints News

Precision Pfizer Drug Leads to ‘Unprecedented’ Survival in Colorectal Cancer, Data at ASCO Show

Precision Pfizer Drug Leads to ‘Unprecedented’ Survival in Colorectal Cancer, Data at ASCO Show

67% Left coverage: 3 sources

Pfizer drug Braftovi achieved statistically significant and clinically meaningful improvement in overall survival for colorectal cancer patients in a Phase 3 clinical trial. The results will be presented Friday during the annual meeting of the American Society of Clinical Oncology. The post Precision Pfizer Drug Leads to ‘Unprecedented’ Survival in Colorectal Cancer, Data at ASCO Show appeared first on MedCity News.Cancer See the Story

Stealth BioTherapeutics Announces "Path Forward" Despite Disappointing Delay for Ultra-rare Barth Syndrome

Stealth BioTherapeutics Announces "Path Forward" Despite Disappointing Delay for Ultra-rare Barth Syndrome

100% Center coverage: 4 sources

Following five years of discussions and a positive advisory committee recommendation, FDA proposes a potential accelerated approval pathway requiring resubmission of the elamipretide NDABarth syndrome, a progressive, lethal, pediatric cardioskeletal disease often diagnosed at birth and with no approved therapies,…United States · United States See the Story

EyePoint advances with Duravyu Phase III trial

EyePoint advances with Duravyu Phase III trial

EyePoint has entered the final phase of development for its lead product, Duravyu, announcing the completion of patient enrolment for LUGANO, its pivotal Phase III clinical trial.Lugano · Lugano Read Article

Merck, Daiichi Pull US Application for 'guided Missile' Therapy for Lung Cancer

Merck, Daiichi Pull US Application for 'guided Missile' Therapy for Lung Cancer

Merck and Japan-based Daiichi Sankyo have withdrawn their U.S. application for an experimental lung cancer treatment after it failed to prolong the lives of patients in a...Merck · United States See the Story

Breakthrough FDA Approval: New Liquid Hydrocortisone Treatment Targets 5,000 Pediatric Patients with $50M Market Potential

Breakthrough FDA Approval: New Liquid Hydrocortisone Treatment Targets 5,000 Pediatric Patients with $50M Market Potential

First FDA-approved liquid hydrocortisone offers precise dosing for children with adrenal insufficiency. Immediate launch targets 5,000+ patients. See launch details.United States · United States See the Story

Telesis Bio Announces Licensing Agreement with Regeneron to Adopt Gibson SOLA™ Platform for Rapid On-Site DNA and Gene Synthesis

Telesis Bio Announces Licensing Agreement with Regeneron to Adopt Gibson SOLA™ Platform for Rapid On-Site DNA and Gene Synthesis

100% Center coverage: 1 sources

SAN DIEGO--(BUSINESS WIRE)--May 28, 2025-DNA · San Diego See the Story

EC Approves BMS’ Nivolumab SC Formulation for Solid Tumours

EC Approves BMS’ Nivolumab SC Formulation for Solid Tumours

100% Left coverage: 1 sources

The EC has granted approval for the new subcutaneous (SC) formulation of Bristol Myers Squibb’s (BMS) Opdivo (nivolumab)See the Story

University of Bridgeport and TulsiHub Institute Partner to Launch First-of-Its-Kind Regenerative Medicine Program in Nation

University of Bridgeport and TulsiHub Institute Partner to Launch First-of-Its-Kind Regenerative Medicine Program in Nation

100% Center coverage: 2 sources

BRIDGEPORT, Conn., May 28, 2025 /PRNewswire/ -- University of Bridgeport (UB) is proud to announce a groundbreaking certificate program in the rapidly evolving field of Regenerative Medicine, offered in collaboration with the globally renowned TulsiHub Institute. This 12-week, CE-approved program…United States · United States See the Story